Evidence map›Paper›PMID 25197359›Full record

ArticleInternational journal of clinical and experimental pathology2014

Anti-inflammatory effect of peroxisome proliferator-activated receptor-γ (PPAR-γ) on non-obese diabetic mice with Sjogren's syndrome.

Xiaomei Li, Bei Xu, Yiping Wang, Li Wei

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Lipid Metabolism: An Emerging Player in Sjögren's Syndrome.Clinical reviews in allergy & immunology · 2025
    Review
  3. Article
  4. Peroxisomes Are Highly Abundant and Heterogeneous in Human Parotid Glands.International journal of molecular sciences · 2023
    Article
  5. Article
  6. Sex differences feed into nuclear receptor signaling along the digestive tract.Biochimica et biophysica acta. Molecular basis of disease · 2021
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiaomei LiDepartment of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital Hefei, Anhui Province, P.R. China.
Bei XuDepartment of Rheumatology and Immunology, The Third Affiliated Hospital of Anhui Medical University and The First People's Hospital of Hefei Hefei, Anhui Province, P.R. China.
Yiping WangCentre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney Sydney, New South Wales, Australia.
Li WeiMedicines Monitoring Unit, Division of Medical Sciences, University of Dundee UK DD1 9SY.
University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the anti-inflammatory effect of peroxisome proliferator-activated receptor-γ (PPAR-γ) on non-obese diabetic mice (NOD mice) with Sjogren's syndrome.

methods22 eight-week-old female NOD mice were randomly divided into 2 groups. Rosiglitazone and normal saline were administered in the PPAR-γ group and the control group respectively. At the age of 9, 12 and 15 weeks, one mouse in each group was sacrificed respectively, and the remaining mice were sacrificed at the age of 18 weeks. Blood were obtained by cardiac puncture, and salivary glands were resected. The degree of salivary gland damage and infiltration of lymphocytes were examined by H&E staining. The level of IL-1β, IL-4, IL-6 and TNF-α in serum were measured by ELISA. The mRNA expression level of IL-1β, IL-4, IL-6 and TNF-α in MSG were detected by Real-time PCR. Expression of PPAR-γ in the salivary glands was detected by Immunohistochemistry.

resultsCompared with the control group, mice in the PPAR-γ group showed that (1) histopathologic changes in the salivary glands were significantly ameliorated; (2) at the age of 18 weeks, IL-6 [(25.86 ± 7.32) vs (37.41 ± 11.34)] and TNF-α [(56.88 ± 22.19) vs (78.61 ± 20.76)] were expressed significantly lower and IL-4 [(25.76 ± 12.65) vs (12.11 ± 3.70)] was expressed significantly higher in serum (P < 0.05); (3) the expression of TNF-α was significantly decreased and the expression of IL-4 was significantly increased in MSG (P < 0.05).

conclusionPPAR-γ ameliorates Sjogren's syndrome on NOD mice effectively. The mechanism may be related to the reduction of Th1 cytokines and change of T helper cell balance from Th1 to Th2.

Indexed as

AnimalsAnti-Inflammatory AgentsCytokinesDisease Models, AnimalEnzyme-Linked Immunosorbent AssayFemaleHypoglycemic AgentsImmunohistochemistryMiceMice, Inbred NODPPAR gammaReal-Time Polymerase Chain ReactionRosiglitazoneSjogren's SyndromeThiazolidinedionesAnti-Inflammatory AgentsCytokinesHypoglycemic AgentsPPAR gammaRosiglitazoneThiazolidinedionescytokinesnon-obese diabetic miceperoxisome proliferator-activated receptorsSjogren’s syndrome

Identifiers

PMID25197359
PMCPMC4152049
OpenAlexW2288245219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.